Search research articles
Contact Us
Filters
Showing results (511-520 of 527) with videos related to
Page
of 53
Sort By:
Clinical Trials (London, England)
|
June 7, 2014
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)
Walter T Ambrosius, Kaycee M Sink, Capri G Foy, et al.
The New England Journal of Medicine
|
November 10, 2015
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
, Jackson T Wright, Jeff D Williamson, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
JAMA Cardiology
|
December 29, 2016
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Marshall B Elam, Henry N Ginsberg, Laura C Lovato, et al.
Clinical Trials (London, England)
|
February 26, 2016
Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial
Thomas M Ramsey, Joni K Snyder, Laura C Lovato, et al.
JAMA Internal Medicine
|
December 1, 2015
Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Ravi V Shah, Venkatesh L Murthy, Laura A Colangelo, et al.
The Journal of Clinical Psychiatry
|
May 21, 2020
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie
Georgios Schoretsanitis, John M Kane, Christoph U Correll, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Schizophrenia Research. Cognition
|
December 14, 2019
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures
Michael S Kraus, James M Gold, Deanna M Barch, et al.
Page
of 53
Search research articles
Search
Showing results (511-520 of 527) with videos related to
Sort By:
Page
of 53
Clinical Trials (London, England)
|
June 7, 2014
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)
Walter T Ambrosius, Kaycee M Sink, Capri G Foy, et al.
The New England Journal of Medicine
|
November 10, 2015
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
, Jackson T Wright, Jeff D Williamson, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
JAMA Cardiology
|
December 29, 2016
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Marshall B Elam, Henry N Ginsberg, Laura C Lovato, et al.
Clinical Trials (London, England)
|
February 26, 2016
Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial
Thomas M Ramsey, Joni K Snyder, Laura C Lovato, et al.
JAMA Internal Medicine
|
December 1, 2015
Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Ravi V Shah, Venkatesh L Murthy, Laura A Colangelo, et al.
The Journal of Clinical Psychiatry
|
May 21, 2020
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie
Georgios Schoretsanitis, John M Kane, Christoph U Correll, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Schizophrenia Research. Cognition
|
December 14, 2019
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures
Michael S Kraus, James M Gold, Deanna M Barch, et al.
Page
of 53